---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-026407"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T14:46:58.313323+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aclaris Therapeutics sells 5.7M shares for $20M gross proceeds in ATM offering

## Summary
- 5.7M shares sold on March 10, 2026 for aggregate gross proceeds of $20.0M.
- Purchasers include Frazier Life Sciences, Kalehua Capital, and Adage Capital Partners LP.
- Sale under amended sales agreement with Leerink Partners and Cantor Fitzgerald dated Feb 27, 2025.
- Gross proceeds of $20M implies average price per share of approximately $3.51.

## SEC filing metadata
- accession: 0001104659-26-026407
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000110465926026407/0001104659-26-026407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000110465926026407/acrs-20260310x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-026407
- JSON: https://secwatch.observer/filing/0001104659-26-026407.json
- Plain text: https://secwatch.observer/filing/0001104659-26-026407.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.